**RESEARCH HIGHLIGHT**

**Capturing the perfect pose**

Lipid nanoparticles can be used to deliver nucleic acids for gene expression modulation—but getting them to target specific tissues is an ongoing challenge. In a new study by Dammes et al., a conformation-sensitive targeting strategy is used to achieve better selectivity in silencing gut-homing leukocytes in mouse models of colitis.

The intestinal immune system is continuously faced with a very delicate task: to mount an offense against pathogenic bacteria, while maintaining tolerance towards good bacteria living in the gut. When this fine balance is disrupted, aberrant inflammatory responses cause chronic intestinal inflammation, such as inflammatory bowel disease (IBD). There is no satisfactory cure for IBD yet and blocking cytokines or receptors with antibodies provide only temporary relief. One treatment strategy, which has shown promise, is to change the behaviour of inflammatory leukocytes by rewiring their gene expression. This tricky task can be achieved by delivering nucleic acids capable of silencing gene expression to the affected cells. This fragile cargo (nucleic acids) can be transported to its destination and kept safe from the hostile in vivo environment with lipid nanoparticles (LNPs), frequently used as delivery vehicles. LNPs are especially good candidates with high encapsulation efficiency, low batch-to-batch variation and tendency to easily fuse in membranes. However, LNPs come with one big caveat. Before intravenous injection, they have a tendency to travel straight to the liver and accumulate, making it difficult to direct them to other cell types. Arming these LNPs with additional homing devices can increase their selectivity in reaching the target cells, as shown in a recent study by Dan Peer and colleagues at Harvard Medical School.

Since IFN-γ is known to be causatively involved in colitis, one of the two main forms of IBD, the gene encoding this protein (Ifng) was chosen as the target for gene silencing. Once the target and vehicle were decided, the next important step was to find a homing device that could be used to successfully target the LNPs to the correct inflammatory leukocytes. In IBD, one of the key proteins attracting leukocytes to the gut during intestinal inflammation is α4β7 integrin. Even though this protein is abundant in the intestinal T-cell population and in circulating CD4+ T cells of healthy individuals, it differentiates itself in the diseased state by adopting a specific, high-affinity conformation when activated. The authors cleverly devised a strategy to only target this particular conformation, and consequently increase the specificity of their targeting (Fig. 1). Hence, the mucosal addressin cell adhesion molecule-1 (MAdCAM-1) molecule, which specifically binds to the high-affinity conformation of α4β7 integrin could be the much-needed homing device to their LNP vehicle.

Indeed, the danger associated with insufficient specificity when blocking leukocyte homing is brought into sharp relief by the case of natalizumab, conformation-insensitive monoclonal antibodies against α4β7 integrin, which was temporarily withdrawn from the market for the treatment of IBD, since it increased the risk of severe infection, due to sequestering immune cells. The modified LNPs that specifically target α4β7 integrin-expressing cells in a conformation-dependent manner could be a potential solution to the above grim scenario.

Dan Peer and colleagues began by making a fusion recombinant protein that contained two integrin-binding domains from MAdCAM-1 linked it to LNP using a monoclonal secondary antibody, referred to as RG7. This linker binds MAdCAM-1 protein in such a way that leaves its integrin-binding domain free. Before testing gene silencing in the mouse model of colitis, the authors first went on to confirm the safety of LNPs as delivery vehicles. Indeed, injection of the LNPs did not cause any observable liver toxicity or induce unwanted immune responses. When mice were treated with MAdCAM-1 domain linked LNPs loaded with siIFN-γ, a strong therapeutic response in mice was observed compared to the controls.

Given the chronic nature of IBD and the life-long dependence on medicines for it, non-specific treatments can potentially lead to global immune suppression and sensitise a patient to opportunistic infections. The strategy employed in this study is therefore very smart, since it specifically captures one pose of a protein and thereby improves the specificity of the treatment. Since the relationship between conformational state and protein functionality is a well-known phenomenon, targeting a specific conformation of proteins will open new avenues in precise treatment strategies. The authors have shown us the first step that conformational changes of integrin can be exploited to enhance specificity and cellular uptake, which can translate into therapeutic efficacy in experimental colitis. However, there are still several unanswered questions which might challenge the clinical relevance of this approach, including what percentage of leukocytes assume that conformation, at which location and for how long? What other factors are involved in these chemokine-driven signalling changes which ultimately lead to such conformational changes and, also, can the design of their LNP be improved by replacing the possibly immunogenic rat IgG linker with a more suitable one? These questions aside, there is no doubt that this study presents an exciting approach to developing more specific drug delivery systems by exploiting a very basic feature of protein targeting: their conformational changes.

**Anam Akhtar**

**email:** anam.akhtar@nature.com

Published online: 09 September 2021
References

1. Geremia, A., Biancheri, P., Allan, P., Corazza, G. R. & Di Sabatino, A. Innate and adaptive immunity in inflammatory bowel disease. *Autoimmunity Rev.* **13**, 3–10 (2014).

2. Dammes, N. et al. Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics. *Nat. Nanotechnol.* **1–9**, https://doi.org/10.1038/s41565-021-00928-x (2021).

3. Lichtenstein, G. R., Hanauer, S. B. & Sandborn, W. J. Risk of biologic therapy-associated progressive multifocal leukoencephalopathy: use of the JC virus antibody assay in the treatment of moderate-to-severe Crohn’s disease. *Gastroenterol. Hepatol.* **8**, 1–20 (2012).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© Springer Nature Limited 2021